Veracyte Announces Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 subdued as gains in banks offset AI jitters; Dow at one-month high
- Oil heads for weekly gain with focus on Middle East supply
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Vertiv shares fall on analyst downgrades and options bets
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Stocks edge lower as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
Veracyte, Inc (VCYT) PT Lowered to $28 at Morgan Stanley
August 8, 2025 2:49 PM EDTMorgan Stanley analyst Tejas Savant lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $28.00 (from $29.00) while maintaining a Underweight rating.
The analyst comments "Solid 2Q beat on continued Decipher/Afirma momentum leading to '25 guidance raise; total company guidance now initiated following Veracyte SAS... More



